Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice
- PMID: 7989596
- PMCID: PMC330070
- DOI: 10.1172/JCI117606
Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice
Abstract
To investigate the contribution of IL-1, IL-6, and TNF to the increased osteoclastogenesis induced by estrogen deficiency, ovariectomized (ovx) mice were treated with either IL-1 receptor antagonist (IL-1ra), a competitive inhibitor of IL-1, TNF binding protein (TNFbp), an inhibitor of TNF, or the anti-IL-6 antibody (Ab) 20F3 for the first 2 wk after surgery. ovx increased the bone marrow cells secretion of IL-1 and TNF, but not IL-6, and the formation of TRAP-positive osteoclast-like multinucleated cells (MNCs) in bone marrow cultures treated with 1,25(OH)2D3. The increase in MNC formation induced by ovx was prevented by in vivo treatment with either 17 beta estradiol, IL-1ra, TNFbp, or anti-IL-6 Ab. However, the percent change in MNC formation induced by the anti-IL-6 Ab was similar in ovx and sham-operated animals, whereas IL-1ra and TNFbp were effective only in ovx mice. MNC formation was also decreased by in vitro treatment of bone marrow cultures with IL-1ra and TNFbp, but not with anti-IL-6 Ab. Ovx also increased bone resorption in vivo and in vitro, as assessed by the urinary excretion of pyridinoline cross links and the formation of resorption pits, respectively. IL-1ra, TNFbp and estrogen decreased bone resorption in vivo and in vitro whereas the anti-IL-6 Ab inhibited bone resorption in vitro but not in vivo. In conclusion, these data indicate that IL-1 and TNF play a direct role in mediating the effects of ovx on osteoclastogenesis and bone resorption. The data also suggest that IL-6 is not essential for increasing bone resorption in the early postovariectomy period.
Similar articles
-
Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period.Endocrinology. 1995 Jul;136(7):3054-61. doi: 10.1210/endo.136.7.7789332. Endocrinology. 1995. PMID: 7789332
-
The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice.J Bone Miner Res. 1997 Jun;12(6):935-41. doi: 10.1359/jbmr.1997.12.6.935. J Bone Miner Res. 1997. PMID: 9169353
-
Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.J Clin Invest. 1994 May;93(5):1959-67. doi: 10.1172/JCI117187. J Clin Invest. 1994. PMID: 8182127 Free PMC article.
-
Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.Rheumatology (Oxford). 2002 Sep;41(9):972-80. doi: 10.1093/rheumatology/41.9.972. Rheumatology (Oxford). 2002. PMID: 12209029 Review.
-
Osteoclast function in Paget's disease and multiple myeloma.Bone. 1995 Aug;17(2 Suppl):57S-61S. doi: 10.1016/8756-3282(95)00179-h. Bone. 1995. PMID: 8579899 Review.
Cited by
-
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.J Clin Invest. 2000 Dec;106(12):1481-8. doi: 10.1172/JCI11176. J Clin Invest. 2000. PMID: 11120755 Free PMC article.
-
Brucella and Osteoarticular Cell Activation: Partners in Crime.Front Microbiol. 2017 Feb 20;8:256. doi: 10.3389/fmicb.2017.00256. eCollection 2017. Front Microbiol. 2017. PMID: 28265268 Free PMC article. Review.
-
Reversal of Growth Arrest With the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children.Ann Surg. 2016 Sep;264(3):421-8. doi: 10.1097/SLA.0000000000001844. Ann Surg. 2016. PMID: 27433905 Free PMC article. Clinical Trial.
-
Labisia pumila Prevents Complications of Osteoporosis by Increasing Bone Strength in a Rat Model of Postmenopausal Osteoporosis.Evid Based Complement Alternat Med. 2012;2012:948080. doi: 10.1155/2012/948080. Epub 2012 Sep 9. Evid Based Complement Alternat Med. 2012. PMID: 22991574 Free PMC article.
-
Mechanism and Prospect of Gastrodin in Osteoporosis, Bone Regeneration, and Osseointegration.Pharmaceuticals (Basel). 2022 Nov 18;15(11):1432. doi: 10.3390/ph15111432. Pharmaceuticals (Basel). 2022. PMID: 36422561 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases